These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38019190)

  • 1. Clinical Factors Affecting Daily Dosage of Desmopressin Orally Disintegrating Tablets in Arginine Vasopressin Deficiency.
    Hoshino Y; Inoue K; Ikeda S; Goshima Y; Tatsushima K; Fukuhara N; Okada M; Nishioka H; Yamada S; Takeuchi Y; Takeshita A
    J Clin Endocrinol Metab; 2024 Feb; 109(3):e983-e996. PubMed ID: 38019190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study.
    Arima H; Oiso Y; Juul KV; Nørgaard JP
    Endocr J; 2013; 60(9):1085-94. PubMed ID: 23811987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desmopressin orally disintegrating tablet in Japanese patients with central diabetes insipidus: a retrospective study of switching from intranasal desmopressin.
    Murakami T; Hatoko T; Nambu T; Matsuda Y; Matsuo K; Yonemitsu S; Muro S; Oki S
    Endocr J; 2014; 61(8):773-9. PubMed ID: 24849384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus.
    Kataoka Y; Nishida S; Hirakawa A; Oiso Y; Arima H
    Endocr J; 2015; 62(2):195-200. PubMed ID: 25382102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comments on "Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study"--efficacy and safety of orally disintegrating desmopressin tablets in patients with central diabetes insipidus.
    Kamoi K
    Endocr J; 2013; 60(9):1115. PubMed ID: 23863202
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program.
    Yamaguchi O; Juul KV; Falahati A; Yoshimura T; Imura F; Kitamura M
    Low Urin Tract Symptoms; 2020 Jan; 12(1):8-19. PubMed ID: 31397969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study.
    Sand PK; Dmochowski RR; Reddy J; van der Meulen EA
    J Urol; 2013 Sep; 190(3):958-64. PubMed ID: 23454404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets.
    Sotoyama M; Uchida S; Kamiya C; Tanaka S; Kashiwagura Y; Hakamata A; Odagiri K; Inui N; Watanabe H; Namiki N
    Chem Pharm Bull (Tokyo); 2019; 67(6):540-545. PubMed ID: 31155559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study.
    Weiss JP; Herschorn S; Albei CD; van der Meulen EA
    J Urol; 2013 Sep; 190(3):965-72. PubMed ID: 23454402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial.
    Yamaguchi O; Nishizawa O; Juul KV; Nørgaard JP
    BJU Int; 2013 Mar; 111(3):474-84. PubMed ID: 23046147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Pharmacodynamics of the Oral Disintegrating Tablet of Desmopressin in Adults with Nocturnal Polyuria: A Pilot Study.
    Goessaert AS; Everaert K; Hoebeke P; Vande Walle J
    Adv Ther; 2015 Sep; 32(9):799-808. PubMed ID: 26412224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buccally Administered Intranasal Desmopressin Acetate for the Treatment of Neurogenic Diabetes Insipidus in Infancy.
    Smego AR; Backeljauw P; Gutmark-Little I
    J Clin Endocrinol Metab; 2016 May; 101(5):2084-8. PubMed ID: 27011115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability in Oral Desmopressin Dose Requirements in Children with Central Diabetes Insipidus.
    Almutlaq N; Eugster EA
    J Pediatr; 2021 Dec; 239():228-230. PubMed ID: 34487771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desmopressin duration of antidiuretic action in patients with central diabetes insipidus.
    Juul KV; Bichet DG; Nørgaard JP
    Endocrine; 2011 Aug; 40(1):67-74. PubMed ID: 21626284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.
    Kim RJ; Malattia C; Allen M; Moshang T; Maghnie M
    Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():115-23. PubMed ID: 16456490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical review: Treatment of neurohypophyseal diabetes insipidus.
    Oiso Y; Robertson GL; Nørgaard JP; Juul KV
    J Clin Endocrinol Metab; 2013 Oct; 98(10):3958-67. PubMed ID: 23884783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment with sublingual desmopressin in two infants with hydranencephaly and central diabetes insipidus].
    Marín GR; Baspineiro B; Vilca I
    Arch Argent Pediatr; 2018 Feb; 116(1):e93-e97. PubMed ID: 29333830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Central Diabetes Insipidus in Disabled Children with Diluted Oral Desmopressin Lyophilisate Formulation Administered Through Nasogastric Tube: A Retrospective Case Series.
    Korkmaz HA; Arya VB; Gönüllü A; Coşkunol F; Ozkan B
    Paediatr Drugs; 2023 Sep; 25(5):595-601. PubMed ID: 37326929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desmopressin Dose Requirements in Adults with Congenital and Acquired Central Diabetes Insipidus.
    Pedersen AN; Andreassen M; Rasmussen AK; Krogh J
    Horm Metab Res; 2024 Mar; 56(3):206-213. PubMed ID: 37879354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose Desmopressin Orally Disintegrating Tablet: Suggested Clinically Meaningful Benefit in Patients with Nocturia Due to Nocturnal Polyuria.
    Weiss JP; van der Meulen EA; Juul KV
    Eur Urol Focus; 2020 Sep; 6(5):1006-1012. PubMed ID: 30470646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.